保护肾脏：糖尿病肾病治疗方法的最新进展
Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy.
作者信息
Davis Kaylan N, Hines Abigail E, Schaefer Margaret C, Naseman Kristina W
机构信息
University of Kentucky College of Pharmacy, Lexington, KY.
University of Kentucky HealthCare, Lexington, KY.
出版信息
Clin Diabetes. 2022 Summer;40(3):305-311. doi: 10.2337/cd21-0090.
Abstract
This article provides an update on pharmacotherapy for diabetic nephropathy. ACE inhibitor or angiotensin 2 receptor blocker therapy is a standard of care for hypertension management in people with diabetes and albuminuria. Additionally, recent trials have elucidated the roles of additional therapeutic agents, including the sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and the recently approved mineralocorticoid receptor antagonist finerenone, in the treatment of chronic kidney disease in people with type 2 diabetes. This article provides an evidence-based review of therapies that may delay the progression of kidney disease in this population, including discussion of recent outcomes trials.
摘要
本文提供了糖尿病肾病药物治疗的最新进展。血管紧张素转换酶抑制剂或血管紧张素2受体阻滞剂疗法是糖尿病和蛋白尿患者高血压管理的标准治疗方法。此外，最近的试验阐明了其他治疗药物的作用，包括钠-葡萄糖协同转运蛋白2抑制剂、胰高血糖素样肽1受体激动剂，以及最近获批的盐皮质激素受体拮抗剂非奈利酮，在2型糖尿病患者慢性肾脏病治疗中的作用。本文对可能延缓该人群肾病进展的治疗方法进行了循证综述，包括对近期疗效试验的讨论。
相似文献
1
Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy.保护肾脏：糖尿病肾病治疗方法的最新进展
Clin Diabetes. 2022 Summer;40(3):305-311. doi: 10.2337/cd21-0090.
2
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.醛固酮受体拮抗剂非奈利酮在糖尿病肾病中的肾脏保护作用。
Endocrinol Metab (Seoul). 2023 Feb;38(1):43-55. doi: 10.3803/EnM.2022.1629. Epub 2023 Feb 27.
3
Mineralocorticoid Antagonism and Diabetic Kidney Disease.醛固酮拮抗剂与糖尿病肾病。
Curr Diab Rep. 2019 Jan 23;19(1):4. doi: 10.1007/s11892-019-1123-8.
4
Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist.选择性盐皮质激素受体拮抗剂非奈利酮的心血管和肾脏结局
Cardiol Ther. 2022 Sep;11(3):337-354. doi: 10.1007/s40119-022-00269-3. Epub 2022 Jun 23.
5
New perspectives in the management of diabetic nephropathy.糖尿病肾病管理的新视角
World J Diabetes. 2024 Jun 15;15(6):1086-1090. doi: 10.4239/wjd.v15.i6.1086.
6
Treatment and practical considerations of diabetic kidney disease.糖尿病肾病的治疗与实际考量
Front Med (Lausanne). 2023 Dec 1;10:1264497. doi: 10.3389/fmed.2023.1264497. eCollection 2023.
7
Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.非甾体类盐皮质激素受体拮抗剂在糖尿病肾病患者中的疗效
Postgrad Med. 2023 Apr;135(3):224-233. doi: 10.1080/00325481.2022.2060598. Epub 2022 Apr 20.
8
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.药物治疗 2 型糖尿病的获益与危害：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068.
9
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.非奈利酮治疗糖尿病肾病患者蛋白尿的疗效：一项随机临床试验。
JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.
10
Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?非奈利酮——作为一种非甾体类盐皮质激素受体拮抗剂，它在治疗糖尿病慢性肾病方面，我们是否已经成功？
Expert Opin Pharmacother. 2021 Jul;22(10):1253-1256. doi: 10.1080/14656566.2021.1904892. Epub 2021 Mar 25.
引用本文的文献
1
Renal Safety of Telminuvo, a Single Pill Combination of Telmisartan and S-amlodipine, in Korean Hypertensive Patients: A Multicenter, Retrospective Cohort Study.替米沙坦与S-氨氯地平单片复方制剂Telminuvo在韩国高血压患者中的肾脏安全性：一项多中心回顾性队列研究
Electrolyte Blood Press. 2025 Jun;23(1):1-10. doi: 10.5049/EBP.2025.23.e1. Epub 2025 May 8.
2
Enhancing therapeutic strategies and drug development for patients with kidney disease.改善肾病患者的治疗策略与药物研发。
Expert Opin Drug Saf. 2025 Jul 4:1-26. doi: 10.1080/14740338.2025.2525970.
3
Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study.HRS-1780在肾功能受损受试者中的药代动力学和安全性：一项多中心、非随机、开放标签研究。
Drug Des Devel Ther. 2025 May 8;19:3751-3761. doi: 10.2147/DDDT.S500384. eCollection 2025.
4
Comprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications.中性内肽酶（NEP）抑制剂综述：设计、构效关系及临床应用
Front Pharmacol. 2024 Dec 23;15:1501407. doi: 10.3389/fphar.2024.1501407. eCollection 2024.
5
Fenestrated Endothelial Cells across Organs: Insights into Kidney Function and Disease.器官间的窗孔内皮细胞：对肾脏功能和疾病的深入了解。
Int J Mol Sci. 2024 Aug 22;25(16):9107. doi: 10.3390/ijms25169107.
本文引用的文献
1
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有糖尿病的慢性肾脏病患者的主要不良肾脏和心血管事件的影响：来自 DAPA-CKD 试验的预先指定分析。
Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7.
2
11. Microvascular Complications and Foot Care: .11. 微血管并发症和足部护理： 。
Diabetes Care. 2021 Jan;44(Suppl 1):S151-S167. doi: 10.2337/dc21-S011.
3
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
4
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.KDIGO 2020慢性肾脏病糖尿病管理临床实践指南
Kidney Int. 2020 Oct;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019.
5
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.达格列净与慢性肾脏病不良结局预防（DAPA-CKD）试验：基线特征。
Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234.
6
Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.用于治疗糖尿病肾病的 SGLT2 抑制剂和 GLP-1 受体激动剂的处方决策算法。
Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1678-1688. doi: 10.2215/CJN.02690320. Epub 2020 Jun 9.
7
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.基于基线肾功能的坎格列净的肾脏、心血管和安全性结局：CREDENCE 随机试验的二次分析。
J Am Soc Nephrol. 2020 May;31(5):1128-1139. doi: 10.1681/ASN.2019111168.
8
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.度拉糖肽与 2 型糖尿病患者的心血管结局（REWIND）：一项双盲、随机、安慰剂对照试验。
Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
9
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
10
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.度拉鲁肽对比甘精胰岛素治疗 2 型糖尿病合并中重度慢性肾脏病患者（AWARD-7）：一项多中心、开放标签、随机试验。
Lancet Diabetes Endocrinol. 2018 Aug;6(8):605-617. doi: 10.1016/S2213-8587(18)30104-9. Epub 2018 Jun 14.
Zotero 插件